Thomas J. Schall

Company: ChemoCentryx

Job title: President, Chief Executive Officer & Chairman of the Board

Seminars:

Success Stories & Lessons Learned: TAVNEOS (Avacopan) – an Oral Inhibitor of the Complement C5a Receptor for the Treatment of ANCAAssociated Vasculitis 4:00 pm

• Providing a disease and biology overview • Sharing experiences from non-clinical and clinical development • Addressing lessons learned from the journeyRead more

day: Day One

Success Stories & Lessons Learned: TAVNEOS (Avacopan) – an Oral Inhibitor of the Complement C5a Receptor for the Treatment of ANCAAssociated Vasculitis 9:00 am

Providing a disease and biology overview Sharing experiences from non-clinical and clinical development Addressing lessons learned from the journeyRead more